- In September 2024, Mitsubishi Gas Chemical Company, Inc. has partnered with Detroit-based health tech firm Alerje, Inc. to enhance allergy care through an emergency medicine and food allergy management platform. This collaboration will help Mitsubishi innovate in the allergy care space, expanding its reach in healthcare technology
- In July 2024, BioVaxys Technology Corp. has signed a binding Letter of Intent with AP Visionaries Inc. to co-develop a proprietary DPX formulation aimed at treating life-threatening food allergies, including those triggered by peanuts, tree nuts, and eggs. This collaboration will help BioVaxys expand its portfolio of immune-educating therapies and advance its innovative allergy treatments
- In February 2024, the FDA has approved Xolair as the first and only treatment for children and adults with one or more food allergies, based on data from the NIH-sponsored Phase III OUtMATCH study. This approval will help the company expand Xolair’s market potential in food allergy treatment and offer a new option for patients
- In January 2024, Inimmune Corporation and Intrommune Therapeutics, Inc. have announced a strategic collaboration to combine Intrommune's peanut oral mucosal immunotherapy (OMIT) with Inimmune's proprietary immunotherapy for rapid allergen desensitization. This partnership will enable both companies to advance their food allergy treatments, accelerating their development of innovative immunotherapies
- In January 2024, Intrommune Therapeutics, has launched a Phase 2 clinical study for INT301, a novel toothpaste aimed at treating peanut allergies. This development will help the company advance its food allergy treatment pipeline and bring innovative solutions to market
